Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.
Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors.
The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Eric Poma |
Contact Details
Address: 4475 Executive Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 794 9600 |
| Website | calidibio.com |
Stock Details
| Ticker Symbol | CLDI |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001855485 |
| CUSIP Number | 320703309 |
| ISIN Number | US3207033099 |
| Employer ID | 86-2967193 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric E. Poma Ph.D. | Chief Executive Officer and Director |
| Andrew C. Jackson | Chief Financial Officer |
| Wendy Pizarro Campbell Esq. | Chief Legal, Chief Corporate Dev, Chief Diversity and Corp Secretary |
| Dr. Boris Minev M.D., Ph.D. | President of Medical and Scientific Affairs |
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations and Chief Scientific Officer |
| Guy Travis Clifton M.D. | Chief Medical Officer, Consultant and Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 23, 2025 | DEF 14A | Other definitive proxy statements |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | PRE 14A | Other preliminary proxy statements |
| May 2, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |